Compare AGIO & RUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGIO | RUN |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2013 | 2015 |
| Metric | AGIO | RUN |
|---|---|---|
| Price | $32.48 | $7.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 21 |
| Target Price | ★ $46.25 | $15.87 |
| AVG Volume (30 Days) | 686.1K | ★ 6.4M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 113.35 |
| EPS | N/A | ★ 1.04 |
| Revenue | $43,011,000.00 | ★ $858,578,000.00 |
| Revenue This Year | $237.78 | $6.51 |
| Revenue Next Year | $92.30 | $1.55 |
| P/E Ratio | ★ N/A | $7.54 |
| Revenue Growth | N/A | ★ 12.97 |
| 52 Week Low | $22.24 | $7.58 |
| 52 Week High | $46.00 | $22.44 |
| Indicator | AGIO | RUN |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 35.06 |
| Support Level | $32.17 | N/A |
| Resistance Level | $35.77 | $8.95 |
| Average True Range (ATR) | 1.18 | 0.34 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 51.25 | 0.35 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.